developments warrant a refined perspective on our outlook, we will engage with the market in a timely and transparent manner. Amid ongoing signals of potential tariff actions on pharmaceuticals by the U.S. administration, we are closely monitoring prospective policy shifts and associated risks. We acknowledge the possible ramifications for our clients and ultimately, for patients, and will be working closely with our clients to develop countermeasures that can be implemented swiftly and effectively. We remain committed to delivering reliable and sustainable results grounded in our resilient business model and robust operational capabilities.Demonstration of Global CDMO Leadership through Strong Order Intake and Proven Client Satisfaction Global Competitiveness Underpinned by Enduring Client Trust and Operational Excellence Building on our commitment to exceptional quality and client-centric execution, we continue to solidify our market leadership by achieving significant business milestones. In January, we entered into a landmark CMO agreement valued at approximately USD 1.4 billion (KRW 2 trillion) with a leading European pharmaceutical company - marking the largest single order in our history, accounting for nearly 40% of our total annual order volume for 2024. Since then, we have been actively engaged in discussions with both existing and prospective clients for additional orders, further reinforcing our growth trajectory. Our CDO business also continues to advance steadily, supported by ongoing advancement of our platform technologies and service capabilities. While sustaining stable collaborations with existing partners, we are broadening our client portfolio, thereby strengthening our position as a fully integrated CDMO through enhanced synergy between our CMO and CDO operations. We are honored to have once again been recognized with the CDMO Leadership Awards by Outsourced Pharma, marking our twelfth consecutive year of distinction. This year, we were named a winner in the "Biologics- Global" category and additionally received the "Best Facility" award, affirming the strength of our manufacturing infrastructure, uncompromising quality standards, and technological expertise. Selected based on direct feedback from global biopharmaceutical clients, this award underscores the trust we have built through consistently delivering high-quality biomedicines and fostering long-term partnerships grounded in reliability and performance. We will continue to strive for excellence by delivering exceptional value to our clients and further strengthening our leadership as a trusted global CDMO.Laying the Groundwork for Future Growth with Sustained Investment and Execution Excellence Strengthening Sustainable Global Leadership through a Three-Pillar Growth Strategy Our antibody-drug conjugate (ADC) facility commenced operations in the first quarter and is running smoothly in line with our plans. By integrating this new capability with our existing antibody manufacturing infrastructure, we are now better positioned to offer more comprehensive solutions to global clients engaged in ADC therapeutics. The construction of our fill & finish line is also progressing as scheduled. This April, we initiated operations at Plant 5, designed to elevate efficiency and operational stability through advanced automation and digital transformation. As part of our broader digital transformation initiatives, we implemented and internalized a state-of-the-art Manufacturing Execution System (MES) within Plant 5, replacing previously manual workflows with a more advanced digital manufacturing infrastructure. Also, we implemented various advanced automated systems to enhance operational efficiency and workplace safety. These enhancements are expected to boost productivity and quality, supporting long-term profitability. Looking ahead, we will focus on ensuring a stable and timely ramp-up of Plant 5, supported by favorable contract discussion

CEO MESSAGE Driven. For Life.AnnouncementDear valued investors and shareholders, This is John Rim from Samsung Biologics. To begin, I would like to extend my heartfelt appreciation for your continued interest and steadfast support of our business.Key Highlights2024 Financial Performance• Posted KRW 4.5T in consolidated revenue (YoY +23%) -Consolidated: Rev. 4,547B, OP. 1,320B (OPM: 29.0%) - Biologics: Rev. 3,497B, OP. 1,321B (OPM: 37.8%) - Bioepis: Rev. 1,538B, OP. 435B (OPM: 28.3%)• Consolidated revenue to grow +20-25% in 2025CDMOSecured 17 of the global top 20 big pharma clients *14 clients in 2023• Exceeded KRW 5T in contract volume *Signed 3 major contracts worth KRW 1T+• Launched 4 new CDO platforms *S-TensifyTM, S-AfuCHOTM, S-OptiChargeTM, S-HiconTM• Surpassed 300 regulatory manufacturing approvals *340 approvals in totalBusiness Expansion• Completion of ADC facility construction• P5 at Biocampus II to be operational in Apr. '25• Investment in PFS Mother-line (CGMP ready by Oct. 27) *Foundational set-up for future global expansion• Continued investments via Life Science Fund *Flagship Pioneening, BrickBio, Latus Bio, Generate BiomedicinesBiosimilar• SB17 (bStelara): EU launch & US FDA approval * Launched in EU, including Germany, Spain, France and the Netherlands• SB15 (bEylea):EC & US FDA approval• SB12 (bSoliris) :US FDA approval• SB16 (bProlia):Positive CHMP opinion *EMA's Committee for Medicinal Products for Human UseToday, Samsung Biologics announced our financial results for the fourth quarter and full year of 2024.Fiscal year 2024 was marked by a global economic slowdown and heightened geopolitical tensions. Despite these challenging environments, Samsung Biologics achieved robust performance through customer-centric services and operational excellence.Most notably, we achieved a transformative milestone by becoming the first company within the Korean biopharmaceutical industry to surpass KRW 4.5 trillion in annual revenue. This unprecedented financial performance, setting a new company record with an impressive 23% year-over-year growth, underscores our cutting-edge expertise, distinctive competencies, and the unwavering confidence our clients place in us, thereby reaffirming our market leadership and global competitiveness.As we embark on 2025, we are proud to announce that we have achieved a record-breaking order worth KRW 2 trillion on January 14th, the highest contract volume in our company's history. This remarkable accomplishment not only reinforces our market leadership but also fuels our continued growth momentum, and we remain dedicated to excellence in customer satisfaction by supporting the reliable supply of critical medicines to patients around the world without any delay.Looking ahead to 2025, we foresee an even more robust financial trajectory, propelled by the successful ramp-up of our Plant 4 coupled with the continued full utilization of Plants 1 through 3. Building on this momentum, we have established an annual revenue growth target of 20~25%, positioning us to surpass KRW 5 trillion mark in consolidated revenue within just 14 years of our founding. We take pride in sharing this positive outlook with our esteemed investors, reaffirming our unwavering commitment to driving sustainable growth, broadening our global presence, and optimizing shareholder value.Sustained and Stable Growth of CDMO Business Record-Breaking Contract Wins, Driven by Exceptional Capabilities and Client TrustWe reached an unprecedented milestone in 2024, surpassing KRW 5 trillion in annual contract wins, collaborating with a number of global pharmaceutical giants across the US, Asia, and Europe. This extraordinary achievement was highlighted by a succession of groundbreaking contracts that underscore our prominence in the global pharmaceutical landscape: a KRW 1.45 trillion agreement with a US-based pharmaceutical company in July, followed by a KRW 1.7 trillion contract with an Asian pharmaceutical company in October. Als

developmentBiosimilar• SB17 (bStelara): Launched in Europe and Korea*15 countries incl. Germany, Spain and Netherlands• SB12 (bSoliris): Approved by US FDA• SB15 (bEylea): Received positive CHMP Opinion*Committee for Medicinal products for Human Use (CHMP) of EMAToday, Samsung Biologics announced our financial results for the third-quarter of 2024.For the first time in the company's history, and the first in the domestic biopharmaceutical industry, Samsung Biologics exceeded KRW 3 trillion in cumulative consolidated revenue by the third quarter. Separate revenues of Samsung Biologics and Bioepis posted growth rates of 21% and 26% year-over-year, respectively, while consolidated revenue grew by 15% year-over-year to KRW 1.2 trillion, with operating profit of KRW 339 billion. With this outstanding accomplishment, we went one step closer to achieving an annual consolidated revenue of KRW 4 trillion for the first time in the history of Korean biopharmaceutical industry.In light of this solid growth momentum, we have raised our annual revenue guidance from 10~15% year-over-year growth to 15~20%. This great feat - raising our guidance for two consecutive years stems from our proactive investment activities to address market demands in a timely manner, our strong competitive edge in speed and execution capability, and solid foundation of our CDMO business, all of which have been maximized through our unique Operational Excellence initiatives.Continuous Growth of CDMO Business Contract Wins Continue, Leveraging Robust CompetitivenessOur CDMO business continued to progress smoothly as always. Contract negotiations with Global Pharma clients, based on strategic partnership, remain ongoing.We achieved a record-setting USD 3.3 billion in total cumulative orders for this year. We pride ourselves on our robust capabilities and strategic foresight, which have solidified our position as a trusted partner within the global pharmaceutical landscape. We finalized a monumental contract worth KRW 1.7 trillion with a pharmaceutical company based in Asia yesterday, marking the largest deal disclosed in our company's history. We have also succeeded in securing one of the top 20 global pharmaceutical companies as our clients, bringing the total number of the top 20 clients to 17. And having already secured partnerships with 17 of the top 20 global pharmaceutical companies, we are now strategically positioning ourselves to further expand our client base across key regions, with an extended focus on the Japanese market. Our recent participation at BIO Japan underscored our commitment to fostering deeper relationships with local clients, recognizing the critical importance of proximity in facilitating collaboration and trust. As we aim to extend our reach to the top 40 global pharmaceutical companies as our clients, we fully understand that cultivating close, enduring partnerships with our Japanese counterparts will be pivotal in driving sustained growth and innovation. By leveraging our proven expertise, we are poised to meet the evolving needs of the biopharmaceutical industry and create lasting value for our clients.Meanwhile, we are advancing our CDO business by bolstering our capabilities in delivering tailored solutions and cutting-edge technology platforms. This quarter, we unveiled S-AfuCHOTM, a platform that enables the production of antibodies with enhanced Antibody-dependent Cellular Cytotoxicity (ADCC), and S-OptiChargeTM, a platform that precisely modulates protein charge variants. More recently, we launched S-HiConTM, a high-concentration formulation platform developed to proactively address the growing market demand for the high-dose biopharmaceuticals.This year, we have launched four new platforms, further elevating our global competitiveness by swiftly and adeptly addressing diverse needs of clients under our new CDO business slogan, 'Agile, Flexible, Focused on You'.Moreover, our company recently attained over 300 global regulatory appr

development focusBiosimilar· SB15 (bEylea): Approved by US FDA *1 FDA approved interchangeable biosimilar . SB17 (bStelara): Approved by US FDA/ EC / Korea MFDS . Expansion of the domestic direct sales portfolio (3-+ 5)Today, we announced our financial results for the second quarter of 2024, another remarkable performance thanks to the smooth ramp-up of our fourth plant, milestone payment received for approvals of Samsung Bioepis' biosimilars pipeline, and a favorable FX environment. The standalone sales growth rates for Samsung Biologics and Samsung Bioepis were 27% and 107% respectively, and our consolidated sales reached KRW 1.16 trillion, marking a 34% growth year-on-year, with operating profit increasing by 71% to KRW 435 billion. On a half-year basis, consolidated sales have surpassed KRW 2 trillion, underscoring the stability and robust execution of Samsung Biologics' strategic vision. We anticipate sales revenue to exceed KRW 4 trillion this year, setting a new record for the Korean pharmaceutical sector and reaffirming our outstanding growth potential and market position.Continued Orders Momentum Major Contract Wins with Leading Pharma CompaniesAs of the end of the second quarter, we have strengthened our strategic partnerships with the global pharmaceutical companies, effectively increasing our global top 20 big pharma CMO client base to include 16 companies in total. Notably, we recently announced the successful signing of several significant contracts with global big pharma companies, and these major transactions have raised our 2024 overall orders amount to an outstanding USD 2.1 billion year-to-date, elevating our total cumulative contract value beyond USD 14 billion. These achievements stand as a testament to robust demand resilience amidst global supply concerns. We take pride in our exceptional business competitiveness and the foundation of positive, collaborative relationships with our clients. Leveraging unparalleled speed, quality, and reliability, we consistently maintain high client satisfaction, further strengthening our partnerships with clients and solidifying our position as the industry leading CDMO in the global market.Capacity Expansion Progress on the Construction of Plant 5 and ADC FacilitiesPlant 5, currently under construction at our Bio Campus II, is on track to commence operations by April next year. Designed as a large-scale facility spanning 96,000 square meters with three floors, approximately 70% of the construction has been completed to date. Adjacent to the plant, we are also concurrently constructing a supporting facility equipped with infrastructure essential for manufacturing processes. This support facility, situated strategically at the center of the campus, is poised to play a pivotal role in optimizing production processes and enhancing efficiency, ensuring swift responsiveness to customer needs. Our endeavor to expand our business capability with ADC is also progressing smoothly. Consisting of a 500L conjugation reactor and one purification line, our ADC conjugation facility is scheduled to start operations by the end of the year. Also, through the Samsung Life Science Fund, we have been investing in biotechs around the world with advanced ADC technologies to secure a competitive edge in the ADC field and proactively address market demands. Through these strategic efforts, we aim to build a comprehensive ADC toolbox, thus broadening the scope of services that we can offer to our clients.Growth of CDO with New Platforms Introduction of SelecTailor™, S-Tensify™, and DEVELOPICK™ Ver. 3.0In order to meet the evolving CDO demands of our growing client base, we are committed to expanding new platforms while continuously improving our existing ones. As part of this effort, we introduced our rebranded SelecTailor™ service package and launched our innovative S-Tensify™ platform. Additionally, we unveiled the revamped version 3.0 of our establi

development of ADC therapeutics. In March, Samsung Biologics received the 2024 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect in recognition of our service and business excellence as a global CDMO company. Based on industry clients' evaluations, we have been awarded in all six performance categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Service Capabilities. We believe that winning the award for 11 consecutive years demonstrates our dedication to client satisfaction and the strong trust we have built with our clients. For the rest of the year, we will remain committed to accelerating our sales operations by leveraging our outstanding CDMO capabilities and track record, and we look forward to providing you with more positive news regarding contract executions.Portfolio Expansion: Continued investments in laying the groundwork for emerging technologies, ADCAs part of our business portfolio expansion, we have recently increased our investment focus in the ADC area. First of all, we will launch development and manufacturing services for ADC therapeutics, both in clinical and commercial stages, utilizing our standalone, dedicated ADC facility that is expected to be operational within 2024. In addition, we are continuing to invest in promising biotech companies in Korea and throughout the world via the Samsung Life Science Fund, a fund jointly established with Samsung C&T and Samsung Bioepis. Following our investments in companies equipped with ADC technology, such as Araris Biotech in Switzerland and AimedBio in Korea, we also invested in BrickBio, a U.S. based company with ADC and CGT technologies in March. In addition to ADC, we plan to study diverse business opportunities across various areas including AAV. Our aim is to accelerate our platform and business growth by investing in ADC facilities and forming strategic partnerships with biotech companies that have advanced and promising ADC technologies.Biosimilar Business: Preparing for product launches and starting direct salesSamsung Bioepis is also making tremendous strides by consistently expanding the coverage of existing products while simultaneously pursuing various initiatives including the development and release of new pipelines as well as starting directs sales in Korea. In January of this year, Samsung Bioepis received the biologics license application (BLA) approval from the Korean Ministry of Food and Drug Safety (MFDS) for SB12 (Soliris biosimilar), which was launched in several European markets in July of last year, and launched the product on April 1st in Korea, marking a step towards direct sales. Additionally, in February, Samsung Bioepis announced a partnership with Samil Pharmaceutical to co-deliver its SB15 (Eylea biosimilar) to the market after receiving BLA approval from MFDS for SB15 as the first Korean company. With this approval, Samsung Bioepis became the first company in Korea that have obtained BLA approval for biosimilars of two global blockbuster products targeting Macular Degeneration - Eylea and Lucentis. Meanwhile, Samsung Bioepis is preparing for the seamless product launch for SB17 (Stelara biosimilar), after receiving marketing authorization for SB17 from the European Commission (EC) in April, two months after getting a positive opinion from the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) in February. On top of that, with additional BLA acceptance of the SB17 by MFDS on April 11th, Samsung Bioepis is on track for a smooth product launch for SB17 both at home and abroad. In March, Samsung Bioepis began direct sales of three anti-TNF biosimilar products for treatment of inflammatory diseases (referencing Remicade, Enbrel, and Humira) in Korea, setting up the stage for having robust sales and marketing system. Lastly, Samsung Bioepis has been conducting a phase 1 clinical study for SB27, a proposed biosimilar referencing Keytruda,

development of management strategies. Dear shareholders, in 2024, Samsung Biologics will continue to pusue our vision "to enrich human life with technology and innovation" based on our long-term growth strategy namely the 'three-dimensional-expansion-strategy', which encompasses expansion plans for capacity, portfolio, and geographic footprint. We will also integrate social responsibility as a global leading CDMO into the core of our business operations to lead and establish a better biopharmaceutcal industry. Additionally, we are committen to flawlessly utiong our business plans to achieve our annual and long term goals successfully, thereby enhancing corporate value while also preparing for a sustainable future. Your continued interest and encouragement going forward is sincerely appreciated, and we wish you and your family good health and happiness. Yours Sincerely, March 15, 2024 President & CEO, Samsung Biologics John Rim

2023 FY CEO IR Newsletterceo ir newsletterdrven. for life.2024.01announcementdear vaued investors and sharedolders,this is john rim from samsung biologics.first of all, l would like to express my gratitude for your continuedinterest and support this year.key highlights2023 financial performancerecord-breaking consolidated operating profit of krw itconsolidated : rev. krw 3,695B(+23% YoY), op 1,114B(+13% YoY)(OPM:30.1%)separate:rev. krw 2,939B(+21% YoY), OP 1,204B(+24% YoY)(OPM:41.0%)cumulative:rev. krw 1,020b(+8% YoY), OP 205B(-11% Yoy)(OPM:20.1%)CDMOplant 4 commenced full operations(240KL)investment decision for plant 5(taget operation in 2025)USD 12B cumulatve contract volume, 14 top 20 big pharma clientsNew CDO service launch(s-chosient,s-glyn, cmc package)business expansionADC facility under construction(taget operation in 2024)US sales offices opened for increased accessibility to clients *new jersey & bostoncontinued investments thorugh lige science Fund: - Araris Biotech(apr.), AimedBio(Sep.)BiosimilarbSoliris(sb12):eu launch in july with direct marketingbhumira(sb5): expansion of formulary coverage in usbstelara(sb17): sandoz to commercialize in us, eu, canadablucentis(sb11):approved as interchangeable by fdaToday, samsung biologics released our annual and fourth-quarter financial results for 2023.2023 was a challenging year due to the volatile macroeconomic environment and soaring interest rates which led to fundingissues for biotech companies, prompting several CDMOs to lower their mid to long-term guidance. Among our CDMO peers, we wer the only one to raise guidance twice this year, delivering on our promise of more than 20% revenue growth. We are certainthat our robust CDMO business, proactive domestic/overseas investments, and steadily growing biosimilar business, all of which may be summed up as our core competency, operational Excellence, contributed significantly to our remarkable performance.Solid CMO business growth:Record high consolidated operating profit of KRW 1 trillion, cumuative contract volume exceeding usd 12 billionOur consolidated operating profit surpassed KRW 1 trillion for the first time since the company's founding in 2011, with a 23% YoY growth in revenue driven by improved production efficiency at fully utilized plants 1-3, and revenue contribution from plant 4 which became fully operational in June 2023. We are proud to be one of the fastest companies to reach the KRW 1 trillion mark in Korea after only 12 years of founding.Despite lingering market concerns over potential overcapacity, our 2023 cumulative contract volume has surpassed USD 12 billion(USD 2.5 billion in 2023 alone), and we have added two more global top 20 pharmaceutical companies as our clients, bringing the total to 14 our of 20. We believe that our top-notch service quality, as evidenced by an outstanding track record and strong client trust built over time, paid off in laying the groundwork for extending our client base.plant 4, which is now fully operational with an additional 180kl of capacity coming online in june 2023, is actively ramping up in accordance with a production schedule developed in close collaboration with clients.also, we broke ground for plant 5 in april 2023, the first plant in bio campus ll, with plans to begin operations in april 2025. we are working industriously to complete the facility within an unprecedented timeline of 24 months in order to meet market demand on time. furthermore, sales activities for plant 4 continue to take place, with the focus now shifting to presales for plant 5. we look forward to delivering exciting news to you by continuing our sales activities in full swing.technological expansion for cdo business:launch of new devlopment platforms(s-chosient, s-glyn)and customized CMC packageour CDO business has been making steadfast progress since its launch in 2018. not only did we upgrade s-dual(bi-specific antibody platform) and developick(developability assessment platform) fro

development. Our investment in AimedBio holds significance because it is our first investment in a domestic biotech company with proprietary technology. Likewise, we plan to gain competitiveness in ADC business effectively through various investments in companies with advanced technologies, in addition to having our proprietary ADC conjugation facility.Biosimilar business on trackOur subsidiary, Samsung Bioepis is also expanding its business by focusing on pipeline development. With product sales steadily increasing due to higher prescription rate for existing products and new product launches, we also expanded coverage for Epysqli (a biosimilar product referencing Soliris, SB12), launched in the EU and for Hadlima (a biosimilar product referencing Humira, SB5), launched in the U.S last July. In addition, we released phase 3 clinical data for Stelara biosimilar (SB17), an autoimmune disease treatment, and entered into a commercialization agreement with one of the global biopharmaceutical companies named Sandoz. We will continue to develop and provide patients with high-quality biosimilar products with bioequivalence to the original products.Constant efforts to develop a more sustainable futureAs a leading company to promote sustainability management for the CDMO industry, Samsung Biologics is making constant efforts to contribute to a more sustainable future. As the company chairing the supply chain sector of the Sustainable Markets Initiative Health Systems Task Force, led by His Majesty King Charles III, we have published an Open Letter, co-signed by the members of SMI Healthcare Systems Task Force including AZ, GSK, and Sanofi. The letter outlines 8 actions urging suppliers to commit to the sustainability targets to achieve Net Zero in the bio-industry. This letter underscores our unwavering commitment to achieving Net Zero as soon as possible. In addition, we joined the Sustainable Aviation Buyers Alliance in September this year to promote investments in Sustainable Aviation Fuel (SAF) and offset carbon emissions in travel and logistics. Samsung Biologics will continue to nurture our core while developing and growing to meet the expectations of our shareholders. Your continued interest and support for our business is greatly appreciated. Thank you.October 25, 2023 President & CEO, Samsung Biologics John Rim

CEO MESSAGE Driven. For Life.SAMSUNG BIOLOGICS 2023. 04IR NewsletterDear Investors,This is John Rim, CEO of Samsung Biologics.I would like to begin by expressing my deep gratitude and appreciation for your continued interest and support in Samsung Biologics.Key HighlightsFinancial Performance (Consolidated)• Steady YoY Sales growth for 13 consecutive quarters since the outbreak of COVID 19 pandemic (Q1'20-Q1'23) CAGR at 52% (20~23)• Revenue: KRW 720.9B (YoY +41%) • Operating Profit: KRW 191.7B (YoY +9%)CMO/CDO• P5 investment in Bio Campus II announced (Mar.)• Strengthened Partnerships with Big Pharmas (CMO, CDO)• Won CDMO Leadership Awards in all 6 Categories (Feb.)• Cum. contract amount reached USD 9.9BBusiness Expansion• Opening of a regional sales office in New Jersey, US (Mar.)* Investment for ADC manufacturing facilities announced (Jan.)• Strategic investment in Araris Biotech via Life Science FundBioepis• Launching of Lucentis biosimilar (SB11) in GER, UK, CA (Mar.)• Positive CHMP Opinion received for Soliris biosimilar (SB12)• Upcoming US launching of Humira Biosimilar (SB5) (Compertitive edge gained by high & low-concentration, prefilled syringe and auto-injector, etc.)Samsung Biologics announced our first quarter financial results, and we are pleased to report quarterly financial performance with consolidated revenue of 720.9 billion won up by 41% YoY and an operating profit of 191.7 billion won up by 9% YoY. Since the beginning of the COVID19 pandemic, sales have increased year on year for 13 consecutive quarters, spurred by significant growth in the CMO business. Based on these solid financial results, we are revising our guidance for our annual revenue growth rate from 10-15%, which we announced this January, to 15%-20% for year 2023.Samsung Biologics has been operating its existing Plants 1 through 3 at full capacity while maximizing operational efficiency and maintaining steady and stable manufacturing output. As a result, we secured CMO contracts with global big pharmas including GSK, Pfizer, and Eli Lilly, to name a few, totaling roughly KRW 500 billion, bringing the total accumulated CMO contract amount to approximately USD 9.9 billion (KRW 13 trillion). We have also been able to enter into a partnership with a large pharmaceutical company in our CDO business and continued to build on our solid track record. Samsung Bioepis, a wholly owned subsidiary of ours since April 2022, has also contributed to our swift top-line growth by broadening revenue streams from the expansion of Lucentis biosimilar (SB11) sales in the United States, and other newly launched markets such as Germany, UK and Canada.Simultaneously, in line with the company's three-dimensional growth strategy, Samsung Biologics continues to augment our differentiated "Super Gap" CDMO competitive edge through expansions in our capacity, geographic presence, and business portfolio.Capacity Expansion | Announcement of investment in Bio Campus II, with the construction of Plant 5Plant 4 construction has been fully on track, with its 60,000L portion going operational in October last year, and the remaining 180,000L to go live in June of this year. We have already sealed a number of large-scale manufacturing contracts with Plant 4, signing 9 clients on 12 products, and are actively negotiating with 29 additional clients on 44 products.The robust demand seen for outsourced biopharmaceutical manufacturing convinced us that the time has come to proac- tively make this investment as part of our expansion strategy in order to further expand our global CMO market leadership. In this regard, we have decided to invest 1.98 trillion won ($1.51 billion) in the construction of our fifth facility in Bio Campus II, which will be located on a 96,000-square-meter plot. This new Plant 5, with a capacity of 180,000L, will break ground in the first half of this year and expected to complete co

development and proactively purchased a plot of land 30% larger than the existing Bio Campus I to lay the groundwork for a large-scale bio complex for future growth. Plant 4 began partial operations in Oct. 2022, and we have secured 11 large-scale manufacturing contracts with 8 global biopharmaceutical companies and are actively negotiating an additional 34 contracts with 26 global major pharmaceutical companies. Based on such strong demand on the horizon, we decided to build our fifth facility even before Plant 4 was fully operational in order to meet our clients' needs in a timely manner. Plant 5 will be the first plant to be housed in Bio Campus II, with a capacity of 180KL, identical to Plant 4's phase 2 large scale design. Bio Campus II - conceptual rendering Plant 5 Construction Plan • Location: Bio Campus II in Songdo, Incheon (Approx. 35.7 million square meters) • Capacity: 180KL (Approx. 9.5 million square meters) • Construction Period (Target): Groundbreaking in Mar. 2023; CGMP ready by Sep. 2025 Expected CAPEX: Approx. KRW 1.98 trillion (incl. production support and utility facilities) With Plant 5, we will integrate simplified and standardized design and processes of our existing plants to save construction time and cost, in addition to optimizing operations. Simultaneously, we aim to introduce even greater competitive advantage and service perfection by incorporating cutting-edge technologies including automated equipment and systems and energy efficiency, while leveraging our deep expertise and know-how gained from the operation of our Bio Campus I plants 1, 2, 3, and 4. Using Plant 5 as a starting point, Samsung Biologics will invest approximately KRW 7 trillion in the development of Bio Campus II, which will include the construction of three additional large-scale mAb manufacturing facilities as well as an Open Innovation center to promote and foster innovative biotechnologies. Furthermore, we will continue to implement various inorganic strategies and pursue portfolio and geographic expansion in order to keep our commitment to being a top-tier biopharmaceutical company. As always, your continuous faith and support in us is greatly appreciated. Sincerely, March 17, 2023 President & CEO John Rim

Dear Investors, This is John Rim, CEO of Samsung Biologics. First and foremost, I would like to express my sincere gratitude and appreciation towards your continued interest and ongoing trust in Samsung Biologics over the past year. In 2022, Samsung Biologics achieved all of its annual targets in existing business divisions and successfully expanded its business scope for long-term, sustainable growth of the company. 2022 Financial Results (Consolidated) Cumulative revenue surpassed KRW 3T *the first and only company among Korean Pharma Revenue: KRW 3,001.3B (YoY +91%) *SBL(separated): KRW 2,437.3B Operating profit: KRW 983.6B (YoY +83%) CMO/CDO Plant 4 partial operations within 23 months of groundbreaking Launched "S-DUALTM and 'DEVELOPICKTM' * Bispecific antibody platform * Drug candidates developability platform Continued orders momentum: Cum. contract amount $9.5B Business Expansion Completion of KRW 3.2T rights offering (Apr.) Full acquisition of Samsung Bioepis (Apr.) Purchase of land for Biocampus II (Jul.) Investments in biotechs via Life Science Fund * Jaguar Gene Therapy (Mar.) and Senda Biosciences (Aug) Biosimilar Business US launch of Lucentis Biosimilar (SB11) (Jun.) FDA approval of high-conc. Humira Biosimilar (SB5) (Aug.) R&D expertise synergizing top-line growth of CDMO biz [A phenomenal fiscal year marked by unprecedented financial performance, with consolidated annual revenue exceeding KRW 3 trillion and an operating profit of around KRW 1 trillion, to be the first and only Korean pharma company to surpass KRW 3 trillion mark in annual sales] Significant and unpredictable volatility from macroeconomic and geopolitical factors has dominated the business environment in 2022. Interest rates were on an upward march, inflation was reaching what appeared at the time to be the generational highs, and exchange rates rose sharply. Despite such an unfavorable business environment, we were able to keep all three plants running at full capacity and maintain industry-leading batch success rates while minimizing product changeover (PCO) based on our operational excellence. As a result, for the first time in a half-year period, we surpassed KRW 1 trillion in revenue and have since broken our own record every quarter. In this regard, we are pleased to announce that we became the first and only Korean pharma company to surpass KRW 3 trillion mark in consolidated annual sales, with an operating profit of around KRW 1 trillion. [Plant 4, the world's largest plant, is on track to be completed within the first half of this year, with active presales activities rapidly locking in capacity.] Last October, Samsung Biologics began partial operations of Plant 4 (60,000 liters), the world's largest bio manufacturing site with a capacity of 240,000 liters, within 23 months after the groundbreaking, which was 6 months faster than the original 29-month timeline. It will be fully operational by the first half of this year, and presales activities have successfully locked in capacity. Prior to the plant's full ramp-up, we signed large-scale manufacturing contract agreements for 11 products with 8 global biopharmaceutical companies, and we are actively communicating with 26 other major clients on approximately 34 products. Based on our key competitive advantages of "speed" and "execution," we will strive to complete Plant 4 construction without a hitch and demonstrate our commitment to meeting client needs in a timely manner in order to solidify our trust-based partnership with our clients. [Taking the leap to become a fully integrated global biopharmaceutical company through active investments and portfolio diversification] In response to rising biopharmaceutical CMO demand, Samsung Biol

Dear Investors, This is John Rim, CEO of Samsung Biologics. I would like to express my deep gratitude and appreciation for your continued interest and support in Samsung Biologics. Q3 Financial Results(consolidated) Revenue : KRW873B(YoY +94%) Operating profit : KRW 324B(YoY +94%) Cumulative revenue surpassed KRW 2T *Outperformed full-year standalone sales of '21(KRW 1.57T) CMO/CDO Plant4 commenced partial operations within 23 months since groundbreaking as planned(Oct.) Proprietary bispecific antibody platform 'S-DUAL'launched(Sep.) Orders momentum: Cum. contract amount of USD 8.5B *173 contracts in total : CMO [73], CDO[100] Business Expansion Land purchase agreement signed for Biocampus 2(Jul) Biotech investments: USD 15M in Senda Biosciences(Aug.) via Life Science Fund Continued sustainability initiatives with ESG focus * ESG Report 2022 released(Jul.), Ecovadis Gold rating achieved(Sep.) Samsung Bioepis Stably managed operations of Bioepis since acquisition FDA approval of high-concentration Hadllima (SB5) (Aug.) Humira biosimilar Synergy from stable manufacturing and R&D expertise [cumulative revenue of 2 trillion won on a consolidated basis] Today, Samsung Biologics announced our third-quarter financial results. Our operational excellence not only enabled our stable manufacturing capabilities by renning all three plants at full capacity, but it also mximized revenue by maintaining industry-leading batch success rates and minimizing product changeover(PCO). We are pleased to report quarterly revenue of 675 billion won(operating profit of 311 billion won) with consolidate quarterly revenue of 873 billion won and operating profit of 325 billion won. [Plant 4's rapid initial phase of 60,000 liters coming on line in Oct. '22, only 23 months from groundbreaking to GMP-ready, demonstrated our competitive edge in speed as the leading CMO with the highest manufacturing capacity in the world'] Since the third dquarter of 2020, when we began construction on Plant 4, the world's largest bio manufacturing site with 240,000 liters of capacity (approx. 238,000m2 of land), we have signed large-scale manufacturing contract agreements for seven products with five global biopharmaceutical companies prior to the plant's full ramp-up. We are also actively communicating with other major global corporations regarding more than 25 products. As a demonstration of our commitment to meet the needs of clients in a timely manner, we began partial operations of Plant 4 this October as originally announced at ground breaking 23 months ago. Based on our key competitive advantages of 'speed' and 'technology,' Samsung Biologics continues to make history in the biopharmaceutical CMO industry with unprecedented achievements and solidifying our position as a global leading CMO. [Expanding and diversifying our path to become the world's best CDMO] In response to the increasing biopharmaceutical CMO demand, Samsung Biologics signed a purchase agreement with Incheon Metropolitan City in July to acquire an additional parcel of land (357,000m2) approximately 30% larger than our current campus (238,000m2). In addition, we have been expanding our CMO production facilities beyond monoclonal antibodies to accommodate a wide range of industry needs. For example, after 7 months of technology transfer and scale-up, we successfully completed our first commercial scale engineering run of an mRNA vaccine drug substance at our newly-built mRNA manufacturing suite at our Songdo headquarters. With this, we are now fully equipped to provide one-stop, end-to-end services for mRNA vaccines in addition to our flagship CMO services for antibody drugs. Furthermore, Samsung Biologics has been steadily introducing a number of proprietary technology platforms, laying a solid foundation for o

development capabilities, we expect to have our portfolio leadership expanded continuously by pursuing a more flexible and accelerated growth strategy. As an extension of our efforts for sustainable management that began in earnest in 2021, we published our second annual ESG report on July 11th to address a wide range of environmental, social, and governance (ESG) activities that had been carried out in the past year in addition to outlining our plans for the upcoming year. Under our mission of ‘Driven. For a Sustainable Life.', we are continuously improving and committing our resources to create a more sustainable environment, build a healthier society, and implement responsible business activities. We will be steadfastly committed to a wide range of socially and environmentally equitable practices to contribute to society with sustainable growth and development. With our pre-emptive and bold investments backed by solid business execution, Samsung Biologics will continue our path forward from the world's best contract development and manufacturing organization (CDMO) to a fully integrated global bio-pharmaceutical company. I would like to express my deepest gratitude for your consistent interest and trust in Samsung Biologics, and greatly appreciate your continued faith and encouragement to support the perpetual growth and sustainable development of all of our businesses. As always, thank you for your support. Sincerely, John Rim President & CEO, Samsung Biologics

development capabilities and its future growth plans, including novel drug development, etc. SUC CE Thanks to the strong support and interest from shareholders and investors, Samsung Biologics successfully completed the rights offering. In return, we will continue our efforts to take a great leap forward to diversify our business portfolio for sustainable growth and ultimately become a global biopharmaceutical company with great responsibilities to better serve our clients, shareholders, and ultimately society. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you Sincerely, John Rim President and CEO, Samsung Biologics

development capabilities and future performance in novel drug development, and the deal will further deliver Samsung Bioepis' sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. We will continue to be in close communication with Biogen to work collaboratively for our future growth together. For the purchase of Bioepsis shares and to fund the company's strategic growth plans, we have decided to raise the capital of KRW 3 trillion by issuing new shares. By expanding our portfolio, we will evolve to become a global biopharmaceutical company as the next growth engine with great responsibilities to better serve our clients, shareholders, and ultimately society. Our company continues to hold the world's largest biomanufacturing capacity since 2019 and is advancing forward through active investment with unparalleled innovation. We are currently building Plant 4 and will begin construction of Plant 5 this year, which will offer multi-modal product services, venturing into expanding business portfolio for cell and gene therapies and next-gen vaccines utilizing mRNA, PDNA and viral vectors, all at a single site, in addition to mRNA DP and DS manufacturing. We are also in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. At a time of great momentum for change and advancement, your continued support is indispensable. We ask for your continued trust and support for the success of Samsung Biologics. Thank you. Sincerely, 2022.1.28 CEO and President of Samsung Biologics John Rim

development Platform 'S-Cellerate TM' to offer clients an integrated and seamless drug development solution resulting in accelerated timelines, improving both economics and convenience. We opened our U.S. R&D Lab in San Francisco in 2020, and are planning to add more labs covering the US East Coast and Europe, etc. We have accumulated 87 CDO contracts since 2018, and have been strengthening our seamless one-stop services to clients with high quality and end-to-end capabilities. Pursue Sustainable Growth to a Top-tier Global Bio Pharma CDMOs in the biopharmaceutical industry are projected to grow rapidly at 10% every year, between 2020 and 2026, as a result of increased outsourcing by global pharmaceutical companies, expanded indications and modalities for drugs, and an increase in the number of biotech companies. To seize the opportunity of increased demand for CDMOS, Samsung Biologics' upmost priority this year is to accelerate Plant 4 operation and lock-in pre-sales. Also, within the first of half of this year, we are planning to operate our mRNA drug substance (DS) manufacturing facility, start the construction of Plant 5 (multi modal services), and purchase additional land for Bio Campus II to prepare for Plant 6, open innovation and beyond. Enhancing ESG (Environmental, Social, Governance) Performance As a global biopharmaceutical company, we have enhanced our efforts on ESG management and made progress in various areas. We established an ESG committee within our Board of Directors, published our first Sustainability Report last June, and earned five ISO certificates in BCMS (Business Continuity Management Systems), Safety, Environment, Energy, and Quality. In recognition of our achievements, we received "A" ESG rating from the Korea Corporate Governance Services (KCGS) and were added to the Dow Jones Sustainability World Index, a first for a Korean pharmaceutical company. Last but not least, we have disclosed our mid-term dividend policy and are committed to continuously improve responsible management to enhance shareholder value. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you Sincerely, John Rim President and CEO, Samsung Biologics

development We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following: 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001 First Sustainability Report Issued Frontier-1.5D Participation ESG Rating 'A Grade' from KCGS Dow Jones Sustainability World Index Inclusion SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays. Thank you. Sincerely, John Rim President and CEO, Samsung Biologics

Development Platform New Technology Platform for Client Success With S-CellerateTM (Sep. 2021) ESG(Environmental, Social, Governance Climate Risk Management 'Frontier 1.5D Project' as part of 2050 Carbon Neutral Initiative Today Samsung Biologics announced another record-high quarterly financial results Despite higher worldwide uncertainties than ever due to the prolonged COVID-19 pandemic, Samsung Biologics continues to provide a stable supply of pharmaceutical products to our valued clients and receive global regulatory approvals, enabled by strong operational excellence while maintaining a safe work environment for our employees. Thanks to these efforts along with a near-full operation of all three plants, Samsung Biologics achieved an outstanding, record-high third quarter earnings of 450.7 billion won in revenue and 167.4 billion won in operating profit, reflecting an increase of 176.1 billion won and 110.9 billion won compared to the same period last year, respectively. Samsung Biologics launched a technology enabled CDO Platform 'S-Cellerate In addition to recording a strong cumulative backlog of $7.1 billion in signed contracts with large pharmaceutical companies such as Roche and MSD this quarter, Samsung Biologics also successfully launched a CDO Platform 'S-Cellerate TM' in September. Through this technology-enabled platform, clients are able to significantly shorten the biopharmaceutical development period while reducing R&D costs from cell line development to IND submission, and Process Characterization (PC) to Biologics License Application (BLA). Our CDO business has achieved 82 signed contracts within three years since its market entry in 2018, and provides end-to-end services for the development of new drugs throughout the entire process, from preclinical to clinical trials and commercial production. Enhancing ESG (Environmental, Social, Governance) Performance In addition, we are operating a committee to proactively respond to climate change and to manage risks associated with energy use. Through the systematic operation of our ESG management system, we continue to monitor the impact of climate change on our business activities while establishing a goal of reducing greenhouse gas units based on production. In September, we announced our participation in the Frontier -1.5D initiative to develop a climate risk management model in a collaborative effort with industrial sector representatives and the financial Supervisory Service and fulfill our responsibility as a leading company in the global CDMO market. We appreciate your continued support and interest in Samsung Biologics. We will continue to devote ourselves to creating a better future for humanity and enriching human lives through innovation and advanced technology. Thank you Sincerely, John Rim President and CEO, Samsung Biologics

development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon. 3-Dimensional Expansion : Capacity / Geography / Portfolio Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment. In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value. Thank you for your continued support. Sincerely, John Rim President and CEO, Samsung Biologics

development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic. Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2, John Rim President and CEO, Samsung Biologicsand near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services. 2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years: Capacity Expansion By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion Geography Expansion Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects. Scope Expansion Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.) For the Next Decade 3-Dimensional Expansion - Business Expansion & Portfolio Diversification Source : JP Morgan Healthcare Conference 2021 Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance. In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics

development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress. Bio CMO/CDO/CRO Champing 2030 As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020

development and manufacturing according to our strict COVID-19 controls and management system. 2020 Q3 Revenue 2,746B KRW(QoQ 11% DOWN, YoY 49% UP) Operating Profit 565B KRW (QoQ 30% DOWN, YoY 139% UP) Profit Before Incom Tax 737B KRW (QoQ 9% UP, YoY 67% UP) Net Profit 561B KRW (QoQ 8% UP, YoY 27% UP) Manufacturing Contracts and Business Performance 4 additional contracts in Q3 11 cumulative contracts in 2020 thus far plant 4 Expansion(august) S-CHOiceTMLaunched(August) Continuing to Strengthen Business Competitiveness Towards Becoming a Super Value Company In August, we announced our Plant 4 expansion, which will have a capacity of 256,000L. With the Plant 4 expansion Samsung Biologics is proactively responding to changes in the global biopharmaceutical market and is strongly positioned as the global No.1 CMO based on production capacity. applying Super Value Company principles in the CDO(contract development)market, we continue to strengthen our competitive edge. Samsung Biologics successfully launched our own cell line, S-CHOiceTM, in August 2020. The S-CHOiceTM cell line results in shorter production times and price competitiveness for our clients. Additionally, to strengthen client satisfaction and bring our contract development services closer to global clients, we are launching a CDO R&D Center in San Francisco, California on October 29th(KST). I encourage you to attend the online grand opening ceremony of our CDO R&D Center. Please register through the link at the bottom of the letter. Samsung Biologics will contnue to innovate to provide qualiy services for clients to support them in their mission to advance life-saving therapies. Thank you, Tae Han Kim President & CEO, Samsung Biologics October 21, 2020 CEO IR Newsletter 2 뿐만 아니라 글로벌 거점과 고객사 확보 역량 강화를 위해 10월 29일 미국 San Francisco에 CDO R&D 센터를 오픈할 계획입니다. 온라인으로 진행되는 본 행사에 관심 있으신 투자자분들은 메일 하단의 '등록'을 통해 참석하실 수 있습니다. 삼성바이오로직스는 앞으로도 지속적인 혁신을 통해 빠른 속도로 양질의 서비스를 제공하며, 보다 높은 기업가치 창출을 위해 최선을 다하겠습니다. Super Value Company를 향한 삼성바이오로직스의 행보에 투자자 여러분들의 따뜻한 관심과 지속적인 성원을 부탁드립니다. 감사합니다. 2020년10월21일 삼성바이오로직스 대표이사 사장 김태한